Sun Pharma to Acquire Organon in Major Deal
SHANGHAI, CHINA – Sun Pharmaceutical Industries, based in India, has announced a significant acquisition of Organon & Co, a company located in New Jersey, for an all-cash deal valued at approximately $11.75 billion, including debt.
Sun Pharma will purchase all of Organon’s outstanding shares at $14 each. This decision comes after a thorough evaluation of strategic options, as noted by Carrie Cox, the executive chair at Organon. She emphasized that the deal offers immediate and significant value for Organon’s shareholders.
Organon, which was spun off from Merck in 2021, focuses on women’s health and biosimilars, boasting over 70 products available in 140 countries worldwide. This move positions Sun Pharma, India’s leading drug manufacturer, among the top 25 global pharmaceutical companies, with projected revenues of $12.4 billion.
Kirti Ganorkar, the managing director at Sun Pharma, mentioned that this acquisition is a strategic step towards enhancing the company’s global presence. With the U.S. being a key market, the buyout is expected to boost Sun Pharma’s product lineup.
Sun Pharma aims to grow its innovative medicines segment, which currently includes products in dermatology, ophthalmology, and onco-dermatology. For the financial year ending March 2025, this sector contributed 20% to Sun Pharma’s total sales, and the acquisition is anticipated to increase that contribution to 27%.
Dilip Shanghvi, the executive chairman of Sun Pharma, highlighted that Organon’s offerings, reach, and capabilities will complement Sun Pharma’s existing portfolio well.
Organon operates in several key markets, including the U.S., Europe, China, Canada, and Brazil, and has six manufacturing sites in the EU and emerging markets.
In the market response, Organon’s shares surged by nearly 31% on Friday, while Sun Pharma’s shares experienced a slight decline of 3.6%.
